SC Launch Inc. has invested $250,000 in Charleston-based NeuroQuest to support the development of its innovative blood test for early screening of asymptomatic Alzheimer's disease.

Target Information

NeuroQuest, based in Charleston, is at the forefront of innovation in the field of dementia diagnostics. The company is developing NeuroScreen®, a groundbreaking blood test designed to accurately and affordably screen for and monitor asymptomatic Alzheimer’s disease. This development marks a significant advancement in early detection methods, addressing a critical need in Alzheimer’s care.

NeuroQuest has garnered attention and support, becoming a member of the South Carolina Research Authority (SCRA) and securing its initial investments totaling $550,000. This investment underscores the potential of NeuroScreen® to revolutionize how we approach Alzheimer’s diagnosis.

Industry Overview

The Alzheimer’s disease landscape in the United States is of growing concern, with approximately 7 million Americans currently diagnosed with the condition. Projecti